SUMMARY All young patients in the Grampian area attending the lymphoma review clinic who had received first line treatment for Hodgkin's disease and had attained complete remission without subsequent relapse were studied between 1980 and 1983. Chemotherapy with MVPP (mustine, vinblastine, procarbazine, and prednisolone) had more severe effects on the fertility of men than that of women; younger women and those taking oral contraceptives were more likely to retain fertility than those over 30 or not taking the pill at the time of chemotherapy, but these two effects could not be differentiated. Premature menopause was common after treatment with MVPP. Mantle radiotherapy had no discernible effect on gonadal function.
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In recent years intensive radiotherapy and chemotherapy have strikingly increased survival in patients with Hodgkin's disease. This advance has been gained at a price, and attention is now focused on the long term side effects of treatment. Of these, secondary acute non-lymphoblastic leukaemia and non-Hodgkin's lymphoma are the most serious. Less immediately threatening, but of major importance to patients, most of whom are young, are impaired fertility and gonadal function, which can have major physical and psychological consequences.
Several studies have indicated that fertility is changed after treatment for Hodgkin's disease.'-" Most of these studies have been carried out at major reference centres, and thus a degree of patient selection has operated. Treatment has not always been standardised, with some patients receiving multiple treatments. In the Grampian area all patients with lymphoma from a population base of 520 000 were diagnosed, staged, and treated by a single unit, and follow up was at a common outpatient clinic. Thus an entire group from one geographic and demographic area was studied, and patients were not subject to any form of selection before treatment other than that of having Hodgkin' s disease. We report on the fertility of all young men and women treated with radiotherapy or chemotherapy from an entire population who were studied up to 12 years after treatment. In men the number of children fathered before and after treatment was recorded. All men were asked to supply samples of semen for analysis; not all complied with this request, but in all serum concentrations of follicle stimulating and luteinising hormones and testosterone were measured serially when they attended for review.
The women had pretreatment and post treatment pregnancies recorded, and follicle stimulating hormone, luteinising hormone, oestradiol-17, and progesterone concentrations were measured often.
They were regarded as having an ovulatory cycle and as being potentially fertile if the progesterone concentration rose above 20 nmoVI (6.3 ng/l) in any cycle.'2 Repeated hormone assays were also used to establish whether patients were menopausal, and they were identified as such if they did not menstruate and their assays showed follicle stimulating hormone and luteinising hormone concentrations >20 mIU/ml. The age at treatment, the interval between treatment, and the most remote point of study were also recorded for all patients.
The steroids were measured by standard radioimmunoassay techniques, [13] [14] [15] using highly specific antisera that did not cross react a great deal with other related steroids in blood. Luteinising hormone and follicle stimulating hormone were also measured by radioimmunoassay using the kits supplied by Serono. This is a double antibody method using polyethylene glycol as a precipitating agent, and the standards are calibrated in terms of first International Reference Preparation 68/40. The lower limit of sensitivity for both proteins is 2 mIU/ml. The range of luteinising hormone for normal men is 2-10 mIU/ml and for menopausal women 20-70 mIU/ml. With the exception of the midcycle peak, the values in the mentrual cycle do not exceed 16 mIU/ml. For follicle stimulating hormone the range in men is 1-8 mIU/ml, and the range during the menstrual cycle does not exceed 10 mIU/ml except at the midcycle peak. The range for menopausal women is 20-100 mIU/ml. The normal range for plasma testosterone in men is 14-42 nmolI (4-0-12*1 ng/ml).
STATISTICAL ANALYSIS
In men the differences in follicle stimulating hormone Table 4 compares all women who remained fertile after treatment with MVPP with those who became infertile. Evidently, not only did a higher proportion of those remaining fertile use oral contraception during treatment but also those remaining fertile came to treatment at a considerably earlier age than did those subsequently found to be infertile; the difference in mean age of those retaining and those losing fertility was not, however, significant (p > 0-05). Table 5 gives details of women were menopausal Luteinising hormone (mIU/ml) 10-2 9-8 9-9 2-9
Testosterone (nmol/l) 13-2 9-2 20-6 1442 Conversion: SI to traditional units-Testosterone: 1 nmol/l 3-5 ng/ml. In such a group mantle radiotherapy had no discernible effect on the fertility of young men and women, but, as might be expected, inverted Y radiotherapy regularly produced sustained infertility in both sexes. Treatment with MVPP given over the usual time produced azoospermia in all men studied, and this persisted for up to 10 years with no recovery. it was accompanied by a sustained and striking increase in follicle stimulating hormone and a less pronounced increase in luteinising hormone and normal testosterone values, suggesting specific destruction of spermatogenesis and partial but incomplete impairment of interstitial cell function. By contrast, treatment with MVPP in women had a less profound effect on fertility, about half the women showing evidence of fertility after treatment. Those remaining fertile when studied were, on average, younger at the time of treatment and more likely to have used oral contraceptives during treatment. These differences between the fertile and infertile groups were not significant, although the trends support those seen in other studies.'6 '' About half the women receiving MVPP became menopausal biochemically, and half of these had characteristic menopausal symptoms. Not surprisingly, those receiving treatment before the age of 30 had a longer interval between treatment and menopause than those treated over the age of 30. Probably, those who showed evidence of fertility after treatment and were not menopausal at the time of study will all, ultimately, have a premature menopause.
Treatment of non-Hodgkin's lymphoma with CVP caused azoospermia, with the characteristic rise of follicle stimulating hormone in a few men. Curiously, treatment of non-Hodgkin's lymphoma with CHOP both in men and in women produced less profound changes in fertility during the period of observation, but numbers were too small to allow conclusions to be drawn about this form of treatment. This simple study indicates the incidence ot impaired gonadal function, which is likely to be of major importance to young patients undergoing treatment for Hodgkin's disease when this is delivered in a general hospital setting and when all the patient population at risk is studied. It provides practical figures of the incidence of the side effects of treatment, which have proved invaluable to us in counselling patients at our clinic. Such data need to be made available for widespread use, and la-ner systematic studies on similarly unselected patients are required.
